Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002) [Phase 1]

View source ↗

Summary

An early-phase study evaluating KW-2449 in patients with acute myeloid leukemia reports on safety, tolerability, and pharmacokinetic/pharmacodynamic data. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• KW-2449 (KW-2449)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Acute Myelogenous Leukemia (AML) | Phase 1 | Status: TERMINATED